Compelling data presented at #ASCO24 by our collaborators at the Dana-Farber Cancer Institute from the DAPHNe trial. In a study of patients with early stage HER2+ breast cancer receiving neoadjuvant paclitaxel/trastuzumab/ pertuzumab (THP), 50 were sequenced with NeXT Personal®, which demonstrated 92% baseline detection (27% of detections were in the ultra-sensitive range below 100 PPM). NeXT Personal was also able to demonstrate neoadjuvant THP treatment effectiveness by showing the treatment had cleared the tumor MRD. #PrecisionOncology #ctDNA #ImmunoTherapy
Hailey Falish
4mo
Invigorating to see so much great science being presented at ASCO last weakened!
Scientific Director at Takeda Oncology
4moNice to finally see WGS used to detect MRD. The 20 plus year old idea of genomic sequencing as a biomarker strategy is finally coming to fruition. And much easier to take sequencial blood draws than difficult to obtain tumor biopsies.